Latest Vertex Pharmaceuticals News & Updates

See the latest news and media coverage for Vertex. We track all announcements, press releases, and industry mentions in real time, all in one place.

Vertex Pharmaceuticals (Vertex)

Biopharmaceutical company developing medicines for serious diseases

vrtx.com

Headquarters: Boston, United States
Founded year: 1989
Company type: Public company
Number of employees: 6,000–10,000
Industry: Pharmaceuticals

Last updated Today

Latest news about Vertex Pharmaceuticals (Vertex)

In short: Vertex completed its $10 billion acquisition of Crinetics Pharmaceuticals and raised its 2026 revenue guidance following strong Q2 results.

Company announcements

September 1 Vertex

Vertex completes Crinetics acquisition and expands executive team

The ten-billion-dollar deal strengthens its therapy pipeline, while three executives assume new roles to drive integration and growth.

August 26 Vertex

Vertex secures Cystic Fibrosis therapy reimbursement in Latvia

The partnership with the national health service grants broad treatment access to eligible patients aged six and older starting in August.

August 3 Vertex

Vertex reports second quarter 2026 financial results

Total revenue rose 12% to $3.33 billion; full-year guidance raised to $13.1-$13.2 billion; acquired Crinetics Pharmaceuticals for $10 billion.

July 9 Vertex

Vertex celebrates FDA approval for CRISPR therapy

The therapy targets sickle cell disease and beta thalassemia in children, with associates instrumental in its development.

Media coverage

September 13 JD Supra

DC Circuit Agrees Vertex Pharmaceuticals' Fertility Support Program Would Violate Anti-Kickback Statute

On September 4, the US Court of Appeals for the DC Circuit ruled that the US Department of Health and Human Services Office of the...

September 4 Archyde

Vertex Pharmaceuticals Stock: Why Casgevy's Pediatric Label Expansion Matters – Archyde

Vertex Pharmaceuticals stock has drawn renewed market scrutiny after the US Food and Drug Administration expanded the approval of Casgevy, a CRISPR/Cas9 gene...

September 2 Investing.com

Vertex Pharmaceuticals shares reach all-time highs at $555.84 By Investing.com

Vertex Pharmaceuticals shares reach all-time highs at $555.84...

September 1 Yahoo Finance

Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform

The completed acquisition adds PALSONIFY and atumelnant to Vertex's portfolio, with the two therapies carrying combined peak annual revenue potential of more than $5 billion...

Never miss news about Vertex

Track Vertex and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Vertex competitors & trending companies

Browse news for competitors to Vertex and other trending companies.